GlassScriptPhysician profile
Stephen Earl Young
NPI 1306844964
$3,541.95
in general payments reported to CMS, 2019-2025
32 companies · $900 in 2025
The $900 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $114 · 2021: $357 · 2022: $246 · 2023: $535 · 2024: $898 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,332.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $975.31 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $392.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $272.60 | 2019-2025 | Trelegy Ellipta |
| Astellas Pharma US INC | $212.78 | 2020-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $207.28 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.07 | 2019-2025 | Jardiance, Stiolto Respimat |
| Abbvie INC. | $109.68 | 2021-2025 | Vraylar |
| Exact Sciences Corporation | $107.76 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $99.11 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $90.48 | 2021-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Abbott Laboratories | $87.86 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $85.37 | 2019-2023 | |
| Dexcom, INC. | $85.23 | 2023-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $79.19 | 2019-2023 | Spravato, Xarelto |
| Amgen INC. | $78.99 | 2019-2025 | Otezla, Repatha, Repatha |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $71.14 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.26 | 2024-2025 | Xifaxan, Trulance |
| Sunovion Pharmaceuticals INC. | $45.49 | 2021 | |
| Edwards Lifesciences Corporation | $36.01 | 2024 | Sapien 3 Ultra Resilia |
| Scilex Pharmaceuticals INC. | $32.79 | 2022-2023 | Ztlido |
| Shield Therapeutics INC | $32.36 | 2023-2025 | Accrufer |
| Axsome Therapeutics, INC. | $29.70 | 2025 | Auvelity |
| Hikma Pharmaceuticals USA | $29.14 | 2023-2025 | Ryaltris |
| Idorsia Pharmaceuticals US INC | $28.68 | 2023-2024 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.54 | 2025 | Caplyta |
| Bioventus LLC | $26.70 | 2022 | |
| Medtronic, INC. | $23.82 | 2024 | Hawkone |
| Otsuka America Pharmaceutical, INC. | $20.39 | 2024 | Rexulti |
| Allergan, INC. | $15.50 | 2019 | |
| Eisai INC. | $13.88 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.80 | 2019 | |
| Amarin Pharma, INC. | $12.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.